Tango Therapeutics develops precision oncology medicines targeting genetically defined cancers.
Tango's drug added on top of Daxib (daraxonrasib) shows further survival improvement in pancreatic cancer, validating combo therapy approach. Daxib establishes new baseline therapy enabling sequential combinations.